Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives Regulatory Clearances in Australia for Line of Oral Appliances

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has been cleared to treat obstructive sleep apnea in Australia; the clearance allows the company to treat all ages, regarding of severity. The Class I clearances were received by Australia’s Therapeutic Goods Administration, which regulates the manufacturing and distribution of therapeutic goods in Australia and is the equivalent to the Food and Drug Administration in the United States. The clearances cover the treatment of snoring and obstructive sleep apnea (mild, moderate and severe) using the entire series of VVOS oral appliances. “These recent clearances provide further validation to our technology and extend the scope of our international market,” said Vivos Therapeutics cofounder and CEO Kirk Huntsman in the press release. “The Australian regulators recognized and accepted the clinical data we presented showing the clinical safety and efficacy of our technology regardless of age or the severity of the OSA. We are progressively moving forward with other domestic and international regulatory agencies with high expectations that our applications will be as well received as they have been in Australia. Poor sleep is a global epidemic. Vivos has developed a safe, comfortable, noninvasive, nonsurgical solution, and we intend to offer it worldwide. We have already received clearances in the United States and Canada, and now Australia will become part of our expanding international network. We will continue to grow and spread into other parts of the world.”

To view the full press release, visit https://ibn.fm/h6Xo0

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution and has proven effective in the treatment of an estimated 27,000 patients worldwide by more than 1,500 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children as well as GM instruments’ NRG Rhinomanometer, the only FDA-approved, four-phase rhinomanometer available in the United States. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.